← All trials
NCT05079022
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Sep 30, 2024
- First posted
- Oct 15, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityReponsible party - principal investigator
- Peking UniversityStudy director
- Beijing CSCO-Allist Cancer Research FoundationCollaborator
- Guangzhou Burning Rock Medical Examination Institute Co., Ltd.Collaborator
- Allist Pharmaceuticals, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.